Volume 11, Number 12—December 2005
Research
Postepizootic Persistence of Venezuelan Equine Encephalitis Virus, Venezuela
Juan-Carlos Navarro*, Gladys Medina†, Clovis Vasquez‡, Lark L. Coffey§, Eryu Wang§, Alexander Suárez*‡, Hernán Biord#, Marlene Salas¶, and Scott C. Weaver§
Table 3
Results of the blocking ELISA to determine VEEV subtypes producing seroconversion in HI- and PRNT-positive bovines from Arismendi municipality, Barinas State, Venezuela*
| Sample no.† | % inhibition of epizootic–specific MAb 1A3A–5 binding at indicated serum dilution |
% inhibition of enzootic–specific MAb 1A1B–9 binding at indicated serum dilution |
||||
|---|---|---|---|---|---|---|
| 1:4 | 1:12 | 1:36 | 1:4 | 1:12 | 1:36 | |
| 156 | 3.0 | 8.5 | –5.0 | 52.4 | 17.8 | –34.3 |
| 158 | 12.4 | 13.9 | –3.6 | 27.0 | –20.4 | –37.0 |
| 166 | 35.6 | 12.5 | 6.2 | 30.7 | 42.7 | –21.0 |
| 167 | 59.6 | 42.0 | 3.7 | 65.7 | 17.1 | –9.9 |
| 172 | –11.7 | –15.4 | –13.8 | 37.5 | 32.1 | –19.0 |
| 175 | 8.2 | 5.0 | 2.1 | 48.5 | 21.5 | –20.0 |
| 178 | 23.1 | 15.1 | 2.2 | 69.7 | 44.9 | –5.9 |
| 204 | –1.1 | –10.8 | –22.4 | 75.8 | 56.4 | 29.7 |
| Negative control† | 4.1 | 6.6 | 5.4 | 15.2 | 23.1 | –5.7 |
| Negative control† | 9.4 | 14.1 | 12.0 | 8.0 | 14.5 | 15.6 |
| Negative control† | 5.8 | 11.4 | 11.3 | 17.5 | 23.2 | 11.0 |
| Positive control† | 18.8 | 9.5 | –8.0 | 65.3 | 51.0 | 29.0 |
| Positive control† | 16.4 | 1.4 | 1.7 | 50.1 | 16.7 | 18.9 |
*ELISA, enzyme-linked immunosorbent assay; VEEV, Venezuelan equine encephalitis virus; HI, hemagglutination-inhibition; PRNT, plaque reduction neutralization test; MAb, monoclonal antibody.
†Negative controls are bovine sera from locations with no history of VEE; positive controls are human sera from virus isolation–confirmed, subtype ID VEEV infections (note that the assay is species–independent).
Page created: February 02, 2012
Page updated: February 02, 2012
Page reviewed: February 02, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.